Should treatment adapt mid-course — or should clinicians stick to trial-proven regimens?
This clip tackles the appeal and the risk of adaptive neoadjuvant strategies, why biomarkers still fall short, and why following DESTINY-Breast11 as designed remains the prudent approach.
Adaptive Neoadjuvant Therapy: Are We Ready Yet?
You may also like
Recommended Videos
